Leflunomide Tablet, Film Coated
Product Images NDC 35573-447

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 35573-447). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Burel Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Leflunomide Tablets 1)

Chemical Structure (Leflunomide Tablets 1)
FDA Label Image

Chemical Structure (Leflunomide Tablets 2)

Chemical Structure (Leflunomide Tablets 2)
FDA Label Image

Figure 1 (Leflunomide Tablets 3)

Figure 1 (Leflunomide Tablets 3)
This is a table with information about clinical trials for treatments of rheumatoid arthritis. The table lists the percentage of patients who were ACR20 responders at the endpoint of each trial. The trials are labeled Trial 1, Trial 2, and Trial 3 and took place over 6 or 12 months. The treatments used in the trials are Leflunomide, Methotrexate, Placebo, and Sulfasalazine.*
FDA Label Image

Figure 2 (Leflunomide Tablets 4)

Figure 2 (Leflunomide Tablets 4)
This text presents a graph or a chart showing the percentage of ACR (American College of Rheumatology) Responders over time, according to Trial 1. The graph may be depicting the effectiveness of a treatment or medication over a period. The last observation carried forward may indicate that missing data was imputed by carrying forward the last non-missing observation.*
FDA Label Image

Figure 3 (Leflunomide Tablets 5)

Figure 3 (Leflunomide Tablets 5)
This is data regarding three trials that involved Leflunomide, methotrexate, sulfasalazine, and the placebo. The text describes the "Change in Sharp Score" for Trial 1, Trial 2, and Trial 3 that took place over 12 and 6 months. The Sharp Score is a scoring system used to evaluate the progression of joint damage in rheumatoid arthritis patients. The text also provides some numerical values for the trials.*
FDA Label Image

Figure 4 (Leflunomide Tablets 6)

Figure 4 (Leflunomide Tablets 6)
FDA Label Image

Pdp (Leflunomide Tablets 7)

Pdp (Leflunomide Tablets 7)
FDA Label Image

Pdp (Leflunomide Tablets 8)

Pdp (Leflunomide Tablets 8)
This appears to be a label for Leflunomide tablets, with dosage instructions and prescription requirements.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.